CBAY Quote, Trading Chart, CymaBay Therapeutics Inc.
home / stock / cbay / cbay quote
$ Last:
Change Percent:
$ Open:
$ Previous Close:
$ High:
$ Low:
0 Volume:
01/01/1970 12:00:00 am Last Trade Date Time:
Quotes are delayed by 15 to 20 minutes.
Last Five Trading Days
| Stock Date | Open Price | Close Price | High | Low | Volume |
|---|---|---|---|---|---|
| 2021-02-25 | 5.01 | 4.86 | 5.075 | 4.75 | 1,539,357 |
| 2021-02-24 | 4.99 | 5.03 | 5.08 | 4.895 | 795,760 |
| 2021-02-23 | 4.98 | 4.83 | 5.05 | 4.63 | 1,673,262 |
| 2021-02-22 | 5.42 | 5.15 | 5.42 | 5.08 | 1,625,426 |
| 2021-02-19 | 5.33 | 5.41 | 5.42 | 5.21 | 1,571,845 |
| 2021-02-18 | 5.44 | 5.32 | 5.44 | 5.16 | 1,724,305 |
| 2021-02-17 | 5.59 | 5.45 | 5.6 | 5.4 | 1,508,443 |
| 2021-02-16 | 5.9 | 5.63 | 5.9 | 5.51 | 1,408,652 |
| 2021-02-15 | 6.01 | 5.8 | 6.11 | 5.63 | 1,769,137 |
| 2021-02-12 | 6.01 | 5.8 | 6.11 | 5.63 | 1,767,523 |
| 2021-02-11 | 6.15 | 6.02 | 6.39 | 5.96 | 1,654,146 |
| 2021-02-10 | 6.25 | 6.14 | 6.56 | 5.96 | 2,883,036 |
| 2021-02-09 | 6.15 | 6.16 | 6.2 | 5.88 | 1,249,406 |
| 2021-02-08 | 6.09 | 6.11 | 6.23 | 5.82 | 1,554,741 |
| 2021-02-05 | 6.24 | 5.89 | 6.2499 | 5.72 | 1,863,195 |
| 2021-02-04 | 5.7959 | 5.86 | 5.95 | 5.645 | 1,546,787 |
| 2021-02-03 | 5.62 | 5.67 | 5.855 | 5.54 | 1,570,423 |
| 2021-02-02 | 5.7 | 5.58 | 5.72 | 5.46 | 781,013 |
| 2021-02-01 | 5.43 | 5.65 | 5.67 | 5.28 | 1,214,788 |
| 2021-01-29 | 5.521 | 5.35 | 5.59 | 5.18 | 1,431,825 |
CymaBay Therapeutics Inc. Company Name:
CBAY Stock Symbol:
NASDAQ Market:
CymaBay Therapeutics Inc. Website:
News, Short Squeeze, Breakout and More Instantly...
-
NEWARK, Calif., Feb. 10, 2021 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management will participate in the SVB Leer...
-
Seladelpar demonstrated anti-cholestatic, anti-inflammatory, and anti-pruritic activity through 3 and 6 months Results highlight the potential for seladelpar to offer patients an efficacious and safe second line treatment option Global 52-week Phase 3 registrat...
-
Image source: The Motley Fool. CymaBay Therapeutics Inc. (NASDAQ: CBAY) Q3 2020 Earnings Call Nov 05, 2020 , 4:30 p.m. ET Operator Continue reading For further details see: CymaBay Therapeutics Inc. (CBAY) Q3 2020 Earnings Call Transcript...